JP Morgan Chase’s Altimmune ALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $367K | Buy |
127,498
+22,966
| +22% | +$97.5K | ﹤0.01% | 5192 |
|
|
2025
Q4 | $377K | Buy |
104,532
+5,341
| +5% | +$23.3K | ﹤0.01% | 5202 |
|
|
2025
Q3 | $374K | Sell |
99,191
-5,506
| -5% | -$21.3K | ﹤0.01% | 5183 |
|
|
2025
Q2 | $405K | Sell |
104,697
-5,814
| -5% | -$31.5K | ﹤0.01% | 4889 |
|
|
2025
Q1 | $553K | Buy |
110,511
+7,571
| +7% | +$48K | ﹤0.01% | 4702 |
|
|
2024
Q4 | $742K | Buy |
102,940
+2,028
| +2% | +$15.5K | ﹤0.01% | 4820 |
|
|
2024
Q3 | $620K | Sell |
100,912
-191,848
| -66% | -$1.3M | ﹤0.01% | 4762 |
|
|
2024
Q2 | $1.95M | Buy |
292,760
+204,323
| +231% | +$1.51M | ﹤0.01% | 3814 |
|
|
2024
Q1 | $900K | Sell |
88,437
-2,358
| -3% | -$24K | ﹤0.01% | 4420 |
|
|
2023
Q4 | $1.02M | Buy |
90,795
+30,467
| +51% | +$127K | ﹤0.01% | 4316 |
|
|
2023
Q3 | $157K | Sell |
60,328
-53,864
| -47% | -$155K | ﹤0.01% | 5214 |
|
|
2023
Q2 | $403K | Buy |
114,192
+38,107
| +50% | +$171K | ﹤0.01% | 4623 |
|
|
2023
Q1 | $321K | Sell |
76,085
-103,013
| -58% | -$1.22M | ﹤0.01% | 4765 |
|
|
2022
Q4 | $2.95M | Sell |
179,098
-471,930
| -72% | -$5.3M | ﹤0.01% | 3255 |
|
|
2022
Q3 | $8.31M | Buy |
651,028
+490,455
| +305% | +$7.24M | ﹤0.01% | 2302 |
|
|
2022
Q2 | $1.88M | Sell |
160,573
-147,016
| -48% | -$907K | ﹤0.01% | 3600 |
|
|
2022
Q1 | $1.87M | Buy |
307,589
+122,021
| +66% | +$899K | ﹤0.01% | 3813 |
|
|
2021
Q4 | $1.7M | Buy |
185,568
+130,971
| +240% | +$1.39M | ﹤0.01% | 3976 |
|
|
2021
Q3 | $617K | Buy |
54,597
+40,316
| +282% | +$490K | ﹤0.01% | 4608 |
|
|
2021
Q2 | $141K | Buy |
14,281
+14,269
| +118,908% | +$195K | ﹤0.01% | 5407 |
|
|
2021
Q1 | $0 | Hold |
12
| – | – | ﹤0.01% | 6033 |
|
|
2020
Q4 | $0 | Buy |
+12
| New | +$141 | ﹤0.01% | 5603 |
|
|
2020
Q3 | – | Sell |
-13,065
| Closed | -$140K | – | 5457 |
|
|
2020
Q2 | $140K | Buy |
+13,065
| New | +$71.8K | ﹤0.01% | 4423 |
|
|
2018
Q1 | – | Sell |
-1,935
| Closed | -$116K | – | 5363 |
|
|
2017
Q4 | $116K | Buy |
1,935
+888
| +85% | +$56.7K | ﹤0.01% | 4613 |
|
|
2017
Q3 | $73K | Buy |
+1,047
| New | +$77.9K | ﹤0.01% | 4381 |
|
|
2017
Q2 | – | Sell |
-129
| Closed | -$31K | – | 4935 |
|
|
2017
Q1 | $31K | Sell |
129
-157
| -55% | -$84K | ﹤0.01% | 4635 |
|
|
2016
Q4 | $279K | Buy |
+286
| New | +$256K | ﹤0.01% | 4028 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 4637 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 4674 |
|
Other funds holding ALT
VCM
VPM
N
JP Morgan Chase's ALT Position: Q1 2026 in Review
JP Morgan Chase increased its Altimmune (ALT) stake by 22% in Q1 2026, buying an estimated $97.5K and bringing the position to 127,498 shares worth $367K. The position accounts for ﹤0.01% of the portfolio, ranked #5192.
JP Morgan Chase first reported a position in ALT in Q4 2016 and has held it in 27 quarters since. The position peaked at $8.31M in Q3 2022. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.
- JP Morgan Chase held 127,498 shares of Altimmune worth $367K as of Q1 2026.
- JP Morgan Chase bought 22,966 Altimmune shares in Q1 2026, an estimated $97.5K.
- Altimmune made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5192 holding.
- JP Morgan Chase first reported a position in Altimmune in Q4 2016 and has held it in 27 quarters since.
- JP Morgan Chase's Altimmune position peaked at $8.31M in Q3 2022.
- 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.
Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.